Cocaine

Summary

Cocaine (CHEMBL370805) is an approved small-molecule local anaesthetic (ATC N01BC01) targeting SLC6A3; indicated across 5 conditions including cocaine dependence and opiate dependence.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N01BC01 (+3 more)
• Targets: 1 (SLC6A3)
• Indications: 5 conditions
• Clinical trials: 43
• Chemistry: 303.35 Da · C17H21NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL370805
Name	Cocaine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	446220
ChEBI	CHEBI:27958
ATC	N01BC01, S02DA02, S01HA01, R02AD03
Molecular formula	C17H21NO4
Molecular weight	303.35
InChIKey	ZPUCINDJVBIVPJ-LJISPDSOSA-N

SMILES: CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC

IUPAC name: methyl (1R,2R,3S,5S)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate

ChEBI definition: A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.

Pharmacological roles (ChEBI): local anaesthetic, central nervous system stimulant, sodium channel blocker, adrenergic uptake inhibitor, dopamine uptake inhibitor, serotonin uptake inhibitor, sympathomimetic agent, vasoconstrictor agent.

Other ChEBI roles (chemical / environmental): xenobiotic, environmental contaminant, plant metabolite, mouse metabolite.

Also known as: (r)-(-)-cocaine, Benzoylmethylecgonine, Cocaine, Cocainum, IDS-NC-004, Neurocaine, RX-0041, RX0041, cocaine, COCAINE

Parent form; salt/anhydrous children: CHEMBL529437

Patent coverage: 22,592 distinct patent families (79,531 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	5-HT3AB	Antagonist	4.8
	5-HT3A	Antagonist	5.4
SLC6A3	DAT	Inhibition	7.1	0.2%	Q01959

Broader ChEMBL bioactivity targets: 13 (assay-derived). Sample: Amine oxidase [flavin-containing] A, Sodium channel alpha subunits; brain (Types I, II, III), Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2, Muscarinic acetylcholine receptor M1, Sodium-dependent dopamine transporter, Sigma non-opioid intracellular receptor 1, Sodium-dependent dopamine transporter, Sodium-dependent serotonin transporter, Sodium-dependent dopamine transporter, Sodium-dependent dopamine transporter.

Bioactivity

ChEMBL activities: 375 potent at pChembl ≥ 5 of 383 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P31652	9.3	IC50	0.5	nM	CHEMBL_ACT_1504820
KCNH2	8.36	IC50	4.4	nM	CHEMBL_ACT_309301
P23977	7.5	Ki	32	nM	CHEMBL_ACT_208061
P23977	7.5	Ki	32	nM	CHEMBL_ACT_237181
P23977	7.5	Ki	32	nM	CHEMBL_ACT_353635
P23977	7.5	Ki	32	nM	CHEMBL_ACT_470706
P23977	7.5	Ki	32	nM	CHEMBL_ACT_605618
SLC6A3	7.5	Ki	32	nM	CHEMBL_ACT_70051
P23977	7.5	Ki	32	nM	CHEMBL_ACT_713721
P23977	7.5	Ki	32	nM	CHEMBL_ACT_886980
SLC6A4	7.35	Ki	45	nM	CHEMBL_ACT_1744742
SLC6A4	7.35	Ki	45	nM	CHEMBL_ACT_1839164
SLC6A4	7.35	Ki	45	nM	CHEMBL_ACT_1846567
P31652	7.35	Ki	45	nM	CHEMBL_ACT_496931
P27922	7.19	IC50	65	nM	CHEMBL_ACT_318467
P23977	7.18	IC50	66	nM	CHEMBL_ACT_305357
P23977	7.17	IC50	67.8	nM	CHEMBL_ACT_950133
P23977	7.16	IC50	70	nM	CHEMBL_ACT_1296792
P23977	7.14	Ki	71.8	nM	CHEMBL_ACT_1776188
P23977	7.14	Ki	71.8	nM	CHEMBL_ACT_5208055
P23977	7.13	Ki	74.3	nM	CHEMBL_ACT_1660911
P23977	7.13	Ki	74.3	nM	CHEMBL_ACT_528765
P23977	7.09	IC50	82	nM	CHEMBL_ACT_187038
P23977	7.05	IC50	89	nM	CHEMBL_ACT_1181235
P23977	7.05	IC50	89	nM	CHEMBL_ACT_1206063
P23977	7.05	Ki	89	nM	CHEMBL_ACT_1423094
P23977	7.05	IC50	89.1	nM	CHEMBL_ACT_1510747
SLC6A3	7.05	IC50	89.1	nM	CHEMBL_ACT_1744750
SLC6A3	7.05	IC50	89.1	nM	CHEMBL_ACT_1839160
SLC6A3	7.05	IC50	89.1	nM	CHEMBL_ACT_1846563
SLC6A3	7.05	IC50	89.1	nM	CHEMBL_ACT_2356540
SLC6A3	7.05	IC50	89.1	nM	CHEMBL_ACT_2918209
P23977	7.05	IC50	89.1	nM	CHEMBL_ACT_330467
P23977	7.05	IC50	89	nM	CHEMBL_ACT_330585
P23977	7.05	IC50	89	nM	CHEMBL_ACT_357405
P23977	7.05	IC50	89.1	nM	CHEMBL_ACT_392884
P23977	7.05	IC50	89.1	nM	CHEMBL_ACT_496927
P23977	7.05	IC50	89	nM	CHEMBL_ACT_53230
P23977	7.05	IC50	89	nM	CHEMBL_ACT_635483
P23977	7.05	IC50	89.1	nM	CHEMBL_ACT_656536
P23977	7.05	IC50	89	nM	CHEMBL_ACT_711087
P23977	7.05	IC50	89	nM	CHEMBL_ACT_818443
P23977	7.05	IC50	89.1	nM	CHEMBL_ACT_860776
P23977	7.05	IC50	89.1	nM	CHEMBL_ACT_991270
Q9GJT6	7.02	IC50	95.6	nM	CHEMBL_ACT_143948
P31652	7.02	Ki	95	nM	CHEMBL_ACT_1510749
SLC6A4	7.02	Ki	95	nM	CHEMBL_ACT_2356568
SLC6A4	7.02	Ki	95	nM	CHEMBL_ACT_2918227
SLC6A3	7.02	IC50	95.6	nM	CHEMBL_ACT_645239
P31652	7.02	Ki	96	nM	CHEMBL_ACT_711089
P31652	7.02	Ki	95	nM	CHEMBL_ACT_860778
P23977	7	IC50	101	nM	CHEMBL_ACT_70713
P23977	6.99	IC50	102	nM	CHEMBL_ACT_1284259
P23977	6.99	IC50	102	nM	CHEMBL_ACT_1306071
P23977	6.99	IC50	102	nM	CHEMBL_ACT_278539
P23977	6.99	IC50	102	nM	CHEMBL_ACT_574223
P23977	6.99	IC50	102	nM	CHEMBL_ACT_857857
P23977	6.99	IC50	102	nM	CHEMBL_ACT_930130
P23977	6.99	IC50	102	nM	CHEMBL_ACT_952809
P23977	6.98	IC50	104	nM	CHEMBL_ACT_1616575
SLC6A2	6.97	Ki	108	nM	CHEMBL_ACT_264085
P23977	6.97	IC50	107	nM	CHEMBL_ACT_739884
P23977	6.96	Ki	111	nM	CHEMBL_ACT_1945251
P31652	6.95	Ki	112.1	nM	CHEMBL_ACT_330590
P31652	6.89	Ki	130	nM	CHEMBL_ACT_1223607
SLC6A4	6.89	Ki	129	nM	CHEMBL_ACT_2211738
SLC6A3	6.89	IC50	130	nM	CHEMBL_ACT_2515835
P23977	6.86	IC50	139	nM	CHEMBL_ACT_305354
P27922	6.86	IC50	139	nM	CHEMBL_ACT_670101
P23977	6.84	Ki	146	nM	CHEMBL_ACT_798440
P23977	6.82	IC50	150	nM	CHEMBL_ACT_1504818
P23977	6.82	IC50	150	nM	CHEMBL_ACT_305355
P31652	6.81	Ki	155	nM	CHEMBL_ACT_113430
P31652	6.81	Ki	155	nM	CHEMBL_ACT_1146067
P31652	6.81	Ki	155	nM	CHEMBL_ACT_1252171
P31652	6.81	Ki	155	nM	CHEMBL_ACT_1295911
P31652	6.81	Ki	155	nM	CHEMBL_ACT_1489152
P31652	6.81	Ki	155	nM	CHEMBL_ACT_255068
SLC6A4	6.81	Ki	155	nM	CHEMBL_ACT_264084
P31652	6.81	Ki	155	nM	CHEMBL_ACT_284119
P31652	6.81	Ki	155	nM	CHEMBL_ACT_747672
P31652	6.81	Ki	155	nM	CHEMBL_ACT_788381
P31652	6.81	Ki	155	nM	CHEMBL_ACT_798442
P31652	6.81	Ki	155	nM	CHEMBL_ACT_84700
P31652	6.81	Ki	155	nM	CHEMBL_ACT_856602
P31652	6.81	Ki	155	nM	CHEMBL_ACT_95549
P31652	6.8	Ki	160	nM	CHEMBL_ACT_106602
P31652	6.8	Ki	160	nM	CHEMBL_ACT_1198265
P23977	6.8	IC50	160	nM	CHEMBL_ACT_275620
P23977	6.8	IC50	160	nM	CHEMBL_ACT_727979
P31652	6.8	Ki	160	nM	CHEMBL_ACT_791757
P23977	6.8	IC50	160	nM	CHEMBL_ACT_939594
P31652	6.78	IC50	168	nM	CHEMBL_ACT_1252170
P31652	6.76	Ki	172	nM	CHEMBL_ACT_1190027
P23977	6.76	IC50	173	nM	CHEMBL_ACT_508833
P23977	6.75	IC50	179	nM	CHEMBL_ACT_187039
SLC6A4	6.75	IC50	180	nM	CHEMBL_ACT_2515843
SLC6A2	6.74	Ki	182	nM	CHEMBL_ACT_1946321
P23977	6.73	Ki	187	nM	CHEMBL_ACT_1190025
P23977	6.73	Ki	187	nM	CHEMBL_ACT_446447

Target pathways

Aggregated over 1 target gene(s): SLC6A3.

Top Reactome pathways

13 total, by targets touching each:

Pathway	Targets	Genes
Neurotransmitter clearance	1	SLC6A3
Transmission across Chemical Synapses	1	SLC6A3
Neuronal System	1	SLC6A3
Disease	1	SLC6A3
Dopamine clearance from the synaptic cleft	1	SLC6A3
Transport of small molecules	1	SLC6A3
R-HSA-425366	1	SLC6A3
SLC-mediated transmembrane transport	1	SLC6A3
SLC-mediated transport of neurotransmitters	1	SLC6A3
Defective neurotransmitter clearance by SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS)	1	SLC6A3
SLC transporter disorders	1	SLC6A3
Disorders of transmembrane transporters	1	SLC6A3
Defective transport of neurotransmitters by SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS)	1	SLC6A3

Dominant GO biological processes

GO term	Targets
neurotransmitter transport	1
amino acid transport	1
lactation	1
sensory perception of smell	1
locomotory behavior	1
response to xenobiotic stimulus	1
response to iron ion	1
obsolete monoamine transport	1
obsolete dopamine transport	1
adenohypophysis development	1
response to nicotine	1
sodium ion transmembrane transport	1
positive regulation of multicellular organism growth	1
regulation of dopamine metabolic process	1
response to cocaine	1

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
cocaine dependence	2	MONDO:0005186	EFO:0002610
opiate dependence	2	MONDO:0005530	EFO:0005611
substance withdrawal syndrome	1	MONDO:0005567	EFO:0005800
allergic disease	1	MONDO:0005271	MONDO:0005271

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 43.

Phase distribution

Phase	Trials
PHASE1	15
EARLY_PHASE1	10
PHASE2	5
PHASE4	4
PHASE3	4
Not specified	3
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00000270	PHASE4	WITHDRAWN	Brain Imaging: Cocaine Effects & Medication Development - 5
NCT01706952	PHASE4	COMPLETED	Comparison of Topical Vasoconstriction in Endoscopic Sinus Surgery
NCT03018236	PHASE4	UNKNOWN	Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.
NCT05334017	PHASE4	COMPLETED	Xylometazoline and Cocaine for Nasal Vasoconstriction
NCT04792034	PHASE3	RECRUITING	Pharmacokinetics, Safety, and Tolerability Study of GOPRELTO® Nasal Solution and NUMBRINO™ Nasal Solution
NCT01746940	PHASE3	TERMINATED	Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia
NCT02500836	PHASE3	COMPLETED	Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia
NCT02667054	PHASE3	COMPLETED	Topical Anesthetic for Procedures Through the Nose
NCT00373581	PHASE2	TERMINATED	Effects of Vigabatrin on Cocaine Self-Administration
NCT00373880	PHASE2	COMPLETED	Effects of Aripiprazole on Cocaine Craving and Self-Administration
NCT00656357	PHASE1/PHASE2	COMPLETED	Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers
NCT01778010	PHASE2	COMPLETED	Modafinil for Smoked Cocaine Self-Administration
NCT01846481	PHASE2	COMPLETED	A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse
NCT03192995	PHASE2	TERMINATED	Treatment With Lorcaserin for Cocaine Use: The TLC Study
NCT05809453	PHASE1/PHASE2	COMPLETED	Intranasal Cocaine and Temperature Regulation During Exercise
NCT00000290	PHASE1	COMPLETED	Stress Hormones and Human Cocaine Use - 7
NCT00000292	PHASE1	COMPLETED	Acute Withdrawal From Smoked Cocaine - 9
NCT00000315	PHASE1	COMPLETED	Human Dopamine Transported Imaging in Cocaine Abuse: 1 - 1
NCT00000316	PHASE1	COMPLETED	Human Dopamine Transported Imaging in Cocaine Abuse: 2 - 2
NCT00040066	PHASE1	UNKNOWN	Development of Human Laboratory Study Model of Cocaine Relapse Prevention. - 1
NCT00094315	PHASE1	UNKNOWN	Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1
NCT01851473	PHASE1	COMPLETED	Interactions Between Intravenous Cocaine and Acetazolamide or Quinine
NCT02239913	PHASE1	COMPLETED	Topiramate-Phentermine Combinations for Cocaine Dependence
NCT02393599	PHASE1	COMPLETED	Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin
NCT02522325	PHASE1	COMPLETED	Reinforcing Effects of Cocaine During Phendimetrazine Maintenance
NCT02537873	PHASE1	COMPLETED	Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder
NCT02538744	PHASE1	COMPLETED	Complementary Combination Therapy for Cocaine Dependence
NCT02563769	PHASE1	COMPLETED	Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
NCT02775955	PHASE1	COMPLETED	PK Study of Intranasal RX0041-002 in Subjects With Severe Renal Impairment and Normal Renal Function
NCT03471182	PHASE1	COMPLETED	Investigation of Cocaine Addiction Using mGluR5 PET and fMRI
NCT07086794	EARLY_PHASE1	RECRUITING	Cocaine and Pentoxifylline (BED IN 47)
NCT01906346	EARLY_PHASE1	COMPLETED	Impact of a Non-Drug Choice on Cocaine Reinforcement
NCT01927640	EARLY_PHASE1	COMPLETED	Dexmedetomidine for Reversal of Cocaine’s Effects on the Heart
NCT02141620	EARLY_PHASE1	COMPLETED	n-Acetylcysteine and Cocaine
NCT02233647	EARLY_PHASE1	COMPLETED	Phendimetrazine and Cocaine
NCT02383043	EARLY_PHASE1	COMPLETED	Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer
NCT03519022	EARLY_PHASE1	COMPLETED	Behavioral Effects of Drugs: Inpatient (35)
NCT03937986	EARLY_PHASE1	COMPLETED	Suvorexant and Cocaine
NCT03954938	EARLY_PHASE1	TERMINATED	Behavioral Effects of Drugs (Inpatient): 38
NCT05019430	EARLY_PHASE1	COMPLETED	Cocaine and Zolmitriptan
NCT00451230	Not specified	COMPLETED	Metabolic Effects of Cocaine
NCT01224847	Not specified	COMPLETED	Intravitreal Injection Anesthesia - Comparison of Different Topical Agents
NCT05334056	Not specified	COMPLETED	Drug Test Detection of Cocaine for Nasal Intubation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

482 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
AFATINIB	ChEMBL + PubChem	Phase 4 (approved)	SLC6A3
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	SLC6A3
DACOMITINIB	ChEMBL + PubChem	Phase 4 (approved)	SLC6A3
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	SLC6A3
IDELALISIB	ChEMBL + PubChem	Phase 4 (approved)	SLC6A3
OLODATEROL	ChEMBL + PubChem	Phase 4 (approved)	SLC6A3
PIMAVANSERIN	ChEMBL + PubChem	Phase 4 (approved)	SLC6A3
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	SLC6A3
TAFENOQUINE	ChEMBL + PubChem	Phase 4 (approved)	SLC6A3
UMECLIDINIUM	ChEMBL + PubChem	Phase 4 (approved)	SLC6A3
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	SLC6A3
AMINEPTINE	ChEMBL	Phase 4 (approved)	SLC6A3
AMINOCAPROIC ACID	ChEMBL	Phase 4 (approved)	SLC6A3
AMIODARONE	ChEMBL	Phase 4 (approved)	SLC6A3
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	SLC6A3
AMLODIPINE	ChEMBL	Phase 4 (approved)	SLC6A3
AMODIAQUINE	ChEMBL	Phase 4 (approved)	SLC6A3
AMOXAPINE	ChEMBL	Phase 4 (approved)	SLC6A3
AMPHOTERICIN B	ChEMBL	Phase 4 (approved)	SLC6A3
ANTAZOLINE	ChEMBL	Phase 4 (approved)	SLC6A3
ARFORMOTEROL	ChEMBL	Phase 4 (approved)	SLC6A3
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	SLC6A3
ARMODAFINIL	ChEMBL	Phase 4 (approved)	SLC6A3
ASENAPINE	ChEMBL	Phase 4 (approved)	SLC6A3
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	SLC6A3
ATOMOXETINE	ChEMBL	Phase 4 (approved)	SLC6A3
AXITINIB	ChEMBL	Phase 4 (approved)	SLC6A3
AZELASTINE	ChEMBL	Phase 4 (approved)	SLC6A3
BAZEDOXIFENE	ChEMBL	Phase 4 (approved)	SLC6A3
BEDAQUILINE	ChEMBL	Phase 4 (approved)	SLC6A3
BENDROFLUMETHIAZIDE	ChEMBL	Phase 4 (approved)	SLC6A3
BENFLUOREX	ChEMBL	Phase 4 (approved)	SLC6A3
BENOXINATE	ChEMBL	Phase 4 (approved)	SLC6A3
BENPERIDOL	ChEMBL	Phase 4 (approved)	SLC6A3
BENZBROMARONE	ChEMBL	Phase 4 (approved)	SLC6A3
BENZIODARONE	ChEMBL	Phase 4 (approved)	SLC6A3
BENZPHETAMINE	ChEMBL	Phase 4 (approved)	SLC6A3
BENZTROPINE	ChEMBL	Phase 4 (approved)	SLC6A3
BENZYDAMINE	ChEMBL	Phase 4 (approved)	SLC6A3
BENZYL BENZOATE	ChEMBL	Phase 4 (approved)	SLC6A3
BEPRIDIL	ChEMBL	Phase 4 (approved)	SLC6A3
BEXAROTENE	ChEMBL	Phase 4 (approved)	SLC6A3
BISACODYL	ChEMBL	Phase 4 (approved)	SLC6A3
BITHIONOL	ChEMBL	Phase 4 (approved)	SLC6A3
BOSUTINIB	ChEMBL	Phase 4 (approved)	SLC6A3
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	SLC6A3
BROMHEXINE	ChEMBL	Phase 4 (approved)	SLC6A3
BROMODIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	SLC6A3
BROMPERIDOL	ChEMBL	Phase 4 (approved)	SLC6A3
BROMPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A3
BUPROPION	ChEMBL	Phase 4 (approved)	SLC6A3
BUTOCONAZOLE	ChEMBL	Phase 4 (approved)	SLC6A3
CABERGOLINE	ChEMBL	Phase 4 (approved)	SLC6A3
CALCITRIOL	ChEMBL	Phase 4 (approved)	SLC6A3
CANAGLIFLOZIN	ChEMBL	Phase 4 (approved)	SLC6A3
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	SLC6A3
CANNABIDIOL	ChEMBL	Phase 4 (approved)	SLC6A3
CARBINOXAMINE	ChEMBL	Phase 4 (approved)	SLC6A3
CARIPRAZINE	ChEMBL	Phase 4 (approved)	SLC6A3
CARVEDILOL	ChEMBL	Phase 4 (approved)	SLC6A3
CASPOFUNGIN	ChEMBL	Phase 4 (approved)	SLC6A3
CELECOXIB	ChEMBL	Phase 4 (approved)	SLC6A3
CETIRIZINE	ChEMBL	Phase 4 (approved)	SLC6A3
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	SLC6A3
CHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A3
CHLORPHENTERMINE	ChEMBL	Phase 4 (approved)	SLC6A3
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	SLC6A3
CHLORPROTHIXENE	ChEMBL	Phase 4 (approved)	SLC6A3
CINACALCET	ChEMBL	Phase 4 (approved)	SLC6A3
CINNARIZINE	ChEMBL	Phase 4 (approved)	SLC6A3
CITALOPRAM	ChEMBL	Phase 4 (approved)	SLC6A3
CLEMASTINE	ChEMBL	Phase 4 (approved)	SLC6A3
CLOMIPHENE	ChEMBL	Phase 4 (approved)	SLC6A3
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	SLC6A3
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	SLC6A3
COBIMETINIB	ChEMBL	Phase 4 (approved)	SLC6A3
COLISTIN	ChEMBL	Phase 4 (approved)	SLC6A3
CYCLIZINE	ChEMBL	Phase 4 (approved)	SLC6A3
CYCLOFENIL	ChEMBL	Phase 4 (approved)	SLC6A3
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	SLC6A3
DABIGATRAN ETEXILATE	ChEMBL	Phase 4 (approved)	SLC6A3
DANAZOL	ChEMBL	Phase 4 (approved)	SLC6A3
DASATINIB	ChEMBL	Phase 4 (approved)	SLC6A3
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	SLC6A3
DEQUALINIUM	ChEMBL	Phase 4 (approved)	SLC6A3
DESIPRAMINE	ChEMBL	Phase 4 (approved)	SLC6A3
DESLORATADINE	ChEMBL	Phase 4 (approved)	SLC6A3
DESOGESTREL	ChEMBL	Phase 4 (approved)	SLC6A3
DESVENLAFAXINE	ChEMBL	Phase 4 (approved)	SLC6A3
DEXBROMPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A3
DEXCHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A3
DEXMETHYLPHENIDATE	ChEMBL	Phase 4 (approved)	SLC6A3
DEXTROAMPHETAMINE	ChEMBL	Phase 4 (approved)	SLC6A3
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	SLC6A3
DIMENHYDRINATE	ChEMBL	Phase 4 (approved)	SLC6A3
DIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	SLC6A3
DIPHENYLPYRALINE	ChEMBL	Phase 4 (approved)	SLC6A3
DISULFIRAM	ChEMBL	Phase 4 (approved)	SLC6A3
DOBUTAMINE	ChEMBL	Phase 4 (approved)	SLC6A3
DOMPERIDONE	ChEMBL	Phase 4 (approved)	SLC6A3